← All indications
Diabetes Mellitus
A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
Subtype terms (8)
More specific conditions that are subtypes of Diabetes Mellitus in the MeSH hierarchy.
- Diabetes Complications
49 drugs (34 approved, 15 experimental)
- Diabetes, Gestational
46 drugs (24 approved, 22 experimental)
- Diabetes Mellitus, Experimental
2 drugs approved
- Diabetes Mellitus, Type 1
438 drugs (212 approved, 226 experimental)
- Diabetes Mellitus, Type 2
1169 drugs (347 approved, 822 experimental)
- Donohue Syndrome
- Latent Autoimmune Diabetes in Adults
5 drugs (4 approved, 1 experimental)
- Prediabetic State
230 drugs (85 approved, 145 experimental)
Drugs by status
Approved for this indication (34)
- prazosin
- insulin glargine
- glimepiride
- candesartan
- olmesartan
- calcium cyclamate
- fenofibrate
- sodium chloride
- glucagon
- insulin glulisine
- linagliptin
- benazepril
- rosiglitazone
- lisinopril
- insulin detemir
- valsartan
- telmisartan
- pravastatin
- insulin lispro
- felodipine
- egg albumin-derived peptide
- insulin degludec
- atenolol
- quinapril
- metformin
- ramipril
- insulin human
- verapamil
- enavogliflozin
- liraglutide
- +4 more
Phase 4 trials (196)
- dexmedetomidine
- l-glutamine
- aripiprazole
- rifampin
- propylene glycol
- glucose
- abciximab
- atorvastatin
- tadalafil
- sintrom
- losartan
- mitiglinide
- collagen
- lidocaine
- alpha-ketoacid
- epalrestat
- linaclotide
- allopurinol
- alpha-1 antitrypsin
- vitamin c
- da-5218-c
- sulodexide
- prednisolone
- hydrochlorothiazide
- cobalamin
- plectranthus amboinicus
- semaglutide
- bevacizumab
- midazolam
- apixaban
- +166 more
Phase 3 trials (138)
- diazoxide
- timolol
- droxidopa
- cj30002
- trimetazidine
- brolucizumab-dbll
- epidermal growth factor
- chromium tripicolinate
- morphine
- vitamin k2
- cham
- l-epigallocatechin
- Lumbricus rubellus
- tirzepatide
- cabergoline
- bromfenac
- duloxetine
- denosumab
- ruboxistaurin mesylate
- acetylcysteine
- rexmyelocel-t
- omarigliptin
- succinobucol
- dlbs1449
- pantoprazole
- bone marrow derived mesenchymal stem cells
- stem cells
- beta carotene
- sunflower oil
- papaya
- +108 more
Phase 2 trials (217)
- Veverimer
- paeoniae radix
- pyridostigmine bromide
- topiramate
- hemin
- anastrozole
- ng101m
- nitroglycerin
- yh14617
- cocoa bean
- phentermine
- lotiglipron
- hydroxychloroquine
- cnv-2197944
- ubx1325
- ketamine
- ocn-19
- fuling yunhua
- COVID-19 convalescent plasma
- oshadi r
- rifaximin
- allogeneic pancreatic islet cells
- sodium nitrite
- nnc0114-0006
- ly3852710
- zinc oxide
- dantrolene
- tanezumab
- 111in-exendin
- rucaparib
- +187 more
Phase 1 trials (124)
- bht-3021
- amg 876
- oleic acid
- meropenem
- ketone
- zydpla1
- teneligliptin
- slm0807
- tg103
- acetaminophen
- rgb-5088
- henagliflozin
- date
- sea grape extract
- Retagliptin
- branched chain amino acids
- hti-2088
- xenin-25
- moxifloxacin
- slv341
- allorx stem cells®
- mudan
- harmine
- tedizolid phosphate
- hm12470
- globalagliatin
- ceftolozane
- hyaluronidase (human recombinant)
- pf-04991532
- m28z1xxpd1dnr car
- +94 more
Other trials (190)
- potato
- ambroxol
- varenicline
- whey
- denufosol
- cupric sulfate pentahydrate
- methylcobalamin
- hydrocortisone
- propranolol
- betaine
- Lactobacillus acidophilus
- fish
- peanut
- lactose
- amisulpride
- bifidobacterium animalis
- butenafine
- nitroprusside
- walnut
- amino acids
- bougainvillea
- sitagliptin
- buyuan zhixiao
- sucralose
- baofukang
- enterococcus faecium
- polyherbal
- 1-13c acetate
- colesevelam
- magnesium sulfate
- +160 more
Organizations
Organization Involved with Phase 4 Indications (473)
- University of Palermo
- University of British Columbia
- Medical Research Council, Sweden
- Council of Scientific and Industrial Research, India
- Italian Society of General Practitioners
- Allergan
- Nang Kuang Pharmaceutical Co., Ltd.
- University of Turku
- Andaluz Health Service
- Clinical Research Centre, Malaysia
- Barnsley Hospital
- University of Andalas
- Clinical Research Institute HUCH Ltd
- Jothydev's Diabetes and Research Centre
- Merck KGaA
- Xiamen University
- Sciema
- Steno Diabetes Center Copenhagen
- Merck Serono
- Halozyme Therapeutics
- University of Oulu
- University of Rochester
- KhonKaen University
- Kosin University
- Technion University
- Southern Medical University
- Kyungpook University
- Laval University
- Centre Europeen d'Etude du Diabete
- India Diabetes Research Foundation
- +443 more
Organization Involved with Phase 3 Indications (275)
- Chungnam National University
- Iran University of Medical Sciences
- Tianjin University
- Lecube, Albert, M.D.
- IPPMed
- Diabeteszentrum Bad Lauterberg
- Al Azhar University
- Insulet Corporation
- University of Cincinnati
- University of Lille
- Cinnagen
- DexCom, Inc.
- Melbourne Health
- Virginia Mason Medical Center
- University of Caen-Normandie
- Lexicon Pharmaceuticals
- National Yang-Ming University
- University of Melbourne
- University of Western Australia
- Government of Scotland
- CJ HealthCare Corp.
- Mauritius Ministry of Health and Quality of Life
- Leadiant Biosciences, Inc.
- Metacure
- Mario Negri Institute
- Becton Dickinson
- CenTrial GmbH
- Pharma Nord
- Theracos
- LifeScan
- +245 more
Organization Involved with Phase 2 Indications (342)
- Udayana University
- Yabao Pharmaceutical Group
- Kasturba Medical College
- BioPhage Theraputics Limited
- Evoke Pharma
- Boston Therapeutics
- Ardelyx
- Apex Bioscience
- Clinica Alemana de Santiago
- Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.
- Universidad de El Salvador
- Eastern Virginia Medical School
- Tranzyme, Inc.
- NovMetaPharma Co., Ltd.
- Motus Therapeutics, Inc.
- KinDex Pharmaceuticals, Inc.
- Cebix Incorporated
- Augusta University
- Pioneer Clinical Research LLC
- Institute of Molecular Medicine of Rangueil
- General Electric
- Royan Institute
- Aptabio Therapeutics, Inc.
- Diabetes Research Institute Foundation
- New Orleans Center for Clinical Research
- Repros Therapeutics
- Ng Teng Fong General Hospital
- Wellstat Therapeutics
- Glenmark Pharmaceuticals
- Dance Biopharm Inc.
- +312 more
Organization Involved with Phase 1 Indications (89)
- Ferox Therapeutics
- Stendhal Americas, S.A.
- VitNovo, Inc.
- Neurocrine Biosciences
- Manitoba Medical Service Foundation
- European Commission
- PRACS
- Sadat City University
- Regenerative Medicine Minnesota
- Broad Institute
- Bayhill Therapeutics
- Richmond Pharmacology
- Zhengzhou University
- Perosphere, Inc.
- Centocor
- SeaView Research
- Omni Bio Pharmaceutical, Inc.
- Beijing Chinese Medicine Hospital-Pinggu Hospital
- Beckloff Associates, Inc.
- Institut Cochin
- City of Hope National Medical Center
- Dongguk University
- Alcedis GmbH
- Anhui College of Traditional Chinese Medicine
- ProtoKinetix Inc.
- CAR-T (Shanghai) Biotechnology Co.,Ltd.
- Vanilloid Genetics Inc.
- Al-Neelain University
- Walter and Eliza Hall Institute of Medical Research
- Hubei University of Chinese Medicine
- +59 more
Organization Involved with Other Experimental Indications (205)
- Medanta - The Medicity
- Shidaihuajing Institute
- National University of Malaysia
- Omihachiman COmmunity Medical Center
- Nutrition 21, Inc.
- Institute for Atherosclerosis Research, Russia
- Abertawe Bro Morgannwg University
- Shanghai Municipal Science and Technology Commission
- Baqiyatallah Medical Sciences University
- University of Hull
- Northumbria University
- German Diabetes Foundation, Munich, Germany
- Alpha Therapy Center
- ShiBei Hospital
- Makati Medical Center
- ImmusanT, Inc.
- Scott and White Healthcare
- Sidra Medical and Research Center
- Hochschule Geisenheim University
- Barry Callebaut
- SBI Pharmaceuticals Co, Ltd.
- Jagiellonian University
- Beijing Sino-Japan Friendship Hospital
- University of Kansas
- Federal University of Sao Paulo
- Nemours Children's Health System
- Aboca
- AMCR Institute, Inc.
- Loma Linda University
- Rashid Centre for Diabetes and Research
- +175 more